|
GENVEC RECEIVES FOURTH-YEAR FUNDING FROM NIAID
FOR HIV VACCINE CONTRACT
GAITHERSBURG, MD - September 24, 2009 - GenVec, Inc. (Nasdaq: GNVC) announced
today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National
Institutes of Health (NIH), has executed its third option period (year four) under a previously
announced, five-year contract with GenVec valued at up to $52 million for the production of
HIV vaccines. GenVec will receive up to $2.3 million for the fourth year, which will support the
generation of HIV vaccine candidates with GenVec's alternate adenovirus serotype technology.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines.
GenVec's lead product TNFeradeT is currently in a pivotal clinical study (PACT) in locally
advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its
potential use in the treatment of several other cancers including esophageal cancer, rectal cancer,
and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop
vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory
syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at
www.genvec.com and in the company's various filings with the Securities and Exchange
Commission.
65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735www.genvec.com
Statements herein relating to future financial or business performance, conditions or strategies
and other financial and business matters, including expectations regarding future revenues and
operating expenses, are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to
numerous assumptions, risks and uncertainties, which change over time. Factors that may cause
actual results to differ materially from the results discussed in the forward-looking statements or
historical experience include risks and uncertainties, including the failure by GenVec to secure
and maintain relationships with collaborators; risks relating to the early stage of GenVec's
product candidates under development; uncertainties relating to clinical trials; risks relating to
the commercialization, if any, of GenVec's proposed product candidates; dependence on the
efforts of third parties; dependence on intellectual property; and risks that we may lack the
financial resources and access to capital to fund our operations. Further information on the
factors and risks that could affect GenVec's business, financial conditions and results of
operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission
(SEC), which are available at www.sec.gov. These forward-looking statements speak only as of
the date of this press release, and GenVec assumes no duty to update forward-looking
statements.
###
Investor Contact::
GenVec, Inc.
Danielle M. DiPirro
(301) 944-1877
ddipirro@genvec.com
Media Contact::
Tiberend Strategic Advisors, Inc.
Andrew Mielach
(212) 827-0020
amielach@tiberendstrategicadvisors.com
"Reproduced with permission - GenVec "
GenVec
|
 |
